VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CHEChemed Corporation
$463.28$6.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCHEFinancials

Chemed Corporation (CHE) Financials

30Y historyFree accessUpdated daily

Operating margins have contracted significantly from 19.0% in 2023Q4 to 12.9% in 2026Q1, reflecting structural pressure from rising labor costs and decelerating top-line growth.

CHE Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue2.54B2.53B2.43B2.26B2.13B2.14B2.08B1.94B1.78B1.67B1.58B1.54B1.46B1.41B1.43B1.36B1.28B1.19B1.15B1.1B1.02B915.97M734.88M260.78M253.69M337.91M355.31M453.6M381.3M341.7M301.2M
Revenue Growth %2.07%4.06%7.37%6.06%-0.2%2.87%7.27%8.75%6.96%5.7%2.17%5.98%3.04%-1.17%5.46%5.89%7.59%3.59%4.44%8%11.2%24.64%181.8%2.79%-24.92%-4.9%-21.67%18.96%11.59%13.45%-56.92%
Cost of Goods Sold1.31B1.77B1.58B1.47B1.37B1.37B1.38B1.32B1.23B1.15B1.12B1.09B1.03B1.01B1.03B970.48M906.02M834.57M810.55M767.07M730.12M644.48M506.77M146.82M140.95M205.62M208.98M269.8M230.5M206M178.4M
COGS % of Revenue-70.03%64.86%64.72%64.16%64.02%66.27%68.15%68.87%69.03%70.74%70.47%71.05%71.38%72.26%71.57%70.75%70.12%70.55%69.73%71.68%70.36%68.96%56.3%55.56%60.85%58.82%59.48%60.45%60.29%59.23%
Gross Profit571.36M758.34M854.35M798.82M765.09M769.8M701.39M617.43M555M516.19M461.45M455.78M421.61M404.52M396.72M385.49M374.53M355.66M338.39M332.99M288.46M271.49M228.11M113.96M112.74M132.29M146.33M183.8M150.8M135.7M122.8M
Gross Margin %22.49%29.97%35.14%35.28%35.84%35.98%33.73%31.85%31.13%30.97%29.26%29.53%28.95%28.62%27.74%28.43%29.25%29.88%29.45%30.27%28.32%29.64%31.04%43.7%44.44%39.15%41.18%40.52%39.55%39.71%40.77%
Gross Profit Growth %--11.24%6.95%4.41%-0.61%9.75%13.6%11.25%7.52%11.86%1.24%8.1%4.22%1.97%2.91%2.93%5.3%5.1%1.62%15.44%6.25%19.02%100.17%1.08%-14.78%-9.59%-20.39%21.88%11.13%10.5%-49.21%
Operating Expenses442.21M417.19M487.86M458.25M421.59M426.76M311.71M360.05M311.37M403.16M282.7M271.32M253.19M271.13M240.3M231.76M231.01M229.32M205.54M210.24M183.49M194.72M170.15M105.18M95.6M141.07M116.84M157M130.7M116.1M105.4M
OpEx % of Revenue-16.49%20.07%20.24%19.75%19.95%14.99%18.57%17.47%24.19%17.93%17.58%17.39%19.18%16.8%17.09%18.04%19.27%17.89%19.11%18.01%21.26%23.15%40.34%37.68%41.75%32.88%34.61%34.28%33.98%34.99%
Selling, General & Admin425M417.19M424.36M395.12M358.73M366.73M330.22M305.71M271.21M276.65M248.06M237.82M222.59M215.56M208.66M202.26M201.96M197.43M175.33M184.06M161.18M157.26M147.06M95.36M85.02M104.72M103.46M136.9M113.4M100.9M93.6M
SG&A % of Revenue-16.49%17.45%17.45%16.8%17.14%15.88%15.77%15.21%16.6%15.73%15.41%15.28%15.25%14.59%14.92%15.77%16.59%15.26%16.73%15.82%17.17%20.01%36.57%33.52%30.99%29.12%30.18%29.74%29.53%31.08%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses1000K063.49M63.13M62.86M60.04M-18.51M54.34M40.16M126.5M34.64M33.5M30.6M55.56M31.65M29.5M29.04M31.89M30.2M26.18M22.3M37.46M23.09M9.82M10.58M36.34M13.37M20.1M17.3M15.2M11.8M
Operating Income328.07M338.25M366.49M340.57M343.5M343.04M389.68M257.38M243.63M113.03M178.75M184.46M168.42M133.39M156.42M153.73M143.52M126.34M132.86M122.75M104.98M79.38M58.11M-7.72M-1.55M18.82M33.47M26.8M20.1M19.6M31.3M
Operating Margin %12.91%13.37%15.07%15.04%16.09%16.04%18.74%13.28%13.67%6.78%11.34%11.95%11.56%9.44%10.94%11.34%11.21%10.62%11.56%11.16%10.31%8.67%7.91%-2.96%-0.61%5.57%9.42%5.91%5.27%5.74%10.39%
Operating Income Growth %--7.71%7.61%-0.85%0.13%-11.97%51.4%5.64%115.54%-36.76%-3.09%9.52%26.26%-14.72%1.75%7.11%13.6%-4.9%8.23%16.93%32.24%36.62%852.67%-398.06%-108.24%-43.77%24.88%33.33%2.55%-37.38%-5.15%
EBITDA376.89M403.09M429.54M401.43M402.67M402.09M446.26M302.58M282.5M148.66M213.39M217.96M199.02M162.74M186.94M183.23M172.56M154.25M160.36M148.14M128.78M102.29M78.29M2.1M9.03M40.09M56.91M46.9M37.4M34.8M43.1M
EBITDA Margin %14.84%15.93%17.67%17.73%18.86%18.8%21.46%15.61%15.85%8.92%13.53%14.12%13.67%11.51%13.07%13.51%13.48%12.96%13.96%13.47%12.64%11.17%10.65%0.81%3.56%11.87%16.02%10.34%9.81%10.18%14.31%
EBITDA Growth %-16.65%-6.16%7%-0.31%0.14%-9.9%47.48%7.11%90.03%-30.33%-2.1%9.52%22.3%-12.95%2.03%6.18%11.88%-3.81%8.25%15.03%25.9%30.66%3626.23%-76.72%-77.49%-29.55%21.35%25.4%7.47%-19.26%-15.82%
D&A (Non-Cash Add-back)48.82M64.84M63.05M60.87M59.17M59.05M56.58M45.2M38.86M35.63M34.64M33.5M30.6M29.34M30.52M29.5M29.04M27.9M27.5M25.39M23.8M22.91M20.18M9.82M10.58M21.27M23.45M20.1M17.3M15.2M11.8M
EBIT263.07M357.53M401.25M353.48M334.26M352.18M398.35M266.14M244.59M121.19M180.77M183.77M170.97M138.86M160.54M154.44M145.79M132.22M127.53M113.08M104.98M76.77M57.95M8.77M17.14M15.96M29.49M26.8M20.1M19.6M17.4M
Net Interest Income5.78M7M12.83M3.16M-4.23M-1.49M-1.6M-4.02M-4.32M-3.85M-3.33M-3.36M-8.21M-14.19M-13.91M-13.46M-11.52M-11.18M-11.38M-7.94M00000000000
Interest Income9.63M8.74M14.61M6.27M355K377K757K513K671K427K383K281K0847K809K426K444K423K743K3.3M00000000000
Interest Expense2.45M1.75M1.78M3.11M4.58M1.87M2.35M4.54M4.99M4.27M3.71M3.65M8.21M15.04M14.72M13.89M11.96M11.6M5.99M11.24M00000000000
Other Income/Expense20.88M17.53M32.97M9.8M-13.82M7.28M6.31M4.23M-4.03M3.88M-1.7M-4.33M-5.67M-9.56M-12.94M-13.17M-9.69M-5.72M-10.51M-20.92M-14.7M-24.73M-21.02M7.67M-18.42M-29.14M-2.54M4.2M12M8.3M11M
Pretax Income348.94M355.78M399.46M350.37M329.68M350.31M395.99M261.61M239.6M116.92M177.05M180.13M162.75M123.83M145.82M140.56M133.83M120.62M122.34M101.84M90.28M57.28M37.09M1.25M-1.27M-10.06M33.25M31M32.1M27.9M53.6M
Pretax Margin %13.73%14.06%16.43%15.47%15.44%16.38%19.04%13.5%13.44%7.01%11.23%11.67%11.18%8.76%10.2%10.37%10.45%10.13%10.65%9.26%8.86%6.25%5.05%0.48%-0.5%-2.98%9.36%6.83%8.42%8.17%17.8%
Income Tax89.16M90.54M97.47M77.86M80.06M81.76M76.52M41.69M34.06M18.74M68.31M69.85M63.44M46.6M56.52M54.58M52M46.58M50.24M39.06M32.56M19.58M13.8M4.75M6.85M-3.36M12.66M11.3M12.2M10.8M21.9M
Effective Tax Rate %25.55%25.45%24.4%22.22%24.28%23.34%19.32%15.93%14.21%16.03%38.58%38.78%38.98%37.63%38.76%38.83%38.85%38.62%41.06%38.36%36.07%34.18%37.2%379.92%-537.02%33.41%38.09%36.45%38.01%38.71%40.86%
Net Income259.78M265.24M302M272.51M249.62M268.55M319.47M219.92M205.54M98.18M108.74M110.27M99.32M77.23M89.3M85.98M81.83M73.78M71.02M63.98M50.65M35.82M27.51M-3.44M-1.81M-10.38M20.58M19.7M19.9M30.3M32.3M
Net Margin %10.23%10.48%12.42%12.03%11.69%12.55%15.36%11.34%11.53%5.89%6.9%7.14%6.82%5.46%6.24%6.34%6.39%6.2%6.18%5.82%4.97%3.91%3.74%-1.32%-0.71%-3.07%5.79%4.34%5.22%8.87%10.72%
Net Income Growth %-15.86%-12.17%10.82%9.17%-7.05%-15.94%45.26%7%109.36%-9.72%-1.39%11.03%28.6%-13.52%3.87%5.07%10.91%3.9%11.01%26.31%41.42%30.19%900.93%-89.46%82.53%-150.4%4.49%-1%-34.32%-6.19%39.83%
Net Income (Continuing)259.78M265.24M302M272.51M249.62M268.55M319.47M219.92M205.54M98.18M108.74M110.27M99.32M77.23M89.3M85.98M81.83M74.04M72.11M62.77M57.72M36.23M19.09M11.19M11.11M-10.74M18.64M19.7M19.9M17.1M25.1M
Discontinued Operations00000000000000000000008.33M00000000
Minority Interest00000000000000000000000000000010.8M
EPS (Diluted)19.0018.4219.8917.9316.5316.8519.4813.3112.235.866.486.335.574.164.624.103.553.243.042.551.901.361.12-0.17-0.09-0.531.000.930.991.511.63
EPS Growth %-10.66%-7.39%10.93%8.47%-1.9%-13.5%46.36%8.83%108.7%-9.57%2.37%13.64%33.89%-9.96%12.68%15.49%9.57%6.58%19.22%34.21%39.71%21.43%758.82%-85.39%82.7%-153%7.53%-6.06%-34.44%-7.36%38.14%
EPS (Basic)-18.4220.1018.1116.7217.1420.0213.7712.806.116.646.545.794.244.724.193.623.293.082.611.941.401.14-0.17-0.09-0.531.010.930.991.521.65
Diluted Shares Outstanding13.68M14.4M15.19M15.2M15.1M15.94M16.4M16.53M16.8M16.74M16.79M17.42M17.84M18.59M19.34M20.95M23.03M22.74M23.37M25.08M26.67M26.3M24.64M19.91M19.77M19.43M19.85M21.03M20.2M20.03M19.82M
Basic Shares Outstanding13.68M14.4M15.02M15.05M14.93M15.67M15.96M15.97M16.06M16.06M16.38M16.87M17.16M18.2M18.92M20.52M22.59M22.45M23.06M24.52M26.12M25.55M24.12M19.85M19.72M19.43M19.67M20.94M20.12M19.88M19.58M
Dividend Payout Ratio-11.95%8.97%8.62%8.82%8.2%6.6%9%9.08%17.69%15.12%14.15%14.35%18.32%14.59%14.58%14.52%11.06%7.81%9.2%12.48%17.23%20.78%---19.54%114.21%109.05%69.31%63.16%

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Medicare reimbursement policy shifts

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Facing Structural Headwinds

As reported in recent financial filings, Chemed's year-over-year revenue growth has decelerated to 1.6% in 2026Q1, marking a significant departure from the mid-single-digit expansion observed throughout 2024, suggesting that the post-pandemic referral tailwinds for the VITAS hospice segment may be reaching a point of saturation.

The transition from 9.8% growth in 2025Q1 to current low-single-digit levels indicates that the company is struggling to maintain volume momentum in its core hospice business. Investors should monitor whether this deceleration reflects a broader market shift toward shorter lengths of stay or if it indicates a loss of competitive positioning against regional healthcare providers.

Margin Compression Amid Labor Inflation

Based on the provided income statement data, Chemed's gross margin has experienced notable volatility, falling from a peak of 38.8% in 2023Q4 to recent levels that suggest structural pressure from rising labor costs within the VITAS hospice and Roto-Rooter service operations across the US.

The inability to consistently maintain gross margins above 35% suggests that the company is facing difficulty in passing through wage inflation to government payors and residential customers. This trend warrants further investigation into whether the current cost structure is fundamentally misaligned with the reimbursement environment for hospice care.

Operating Leverage Constrained by Costs

According to historical income statements, Chemed's operating margin has contracted from 19.0% in 2023Q4 to 12.9% in 2026Q1, indicating that the company is currently failing to achieve meaningful operating leverage as SG&A expenses remain sticky despite the slowing pace of top-line revenue expansion.

The lack of scalability in operating income suggests that the company's fixed-cost base is becoming a drag on profitability during periods of slower growth. Analysts should consider whether management's current expense discipline is sufficient to protect bottom-line margins if revenue growth continues to stagnate.

Earnings Volatility and Compensation Impact

As evidenced by the quarterly data, Chemed's net income has shown significant inconsistency, with stock-based compensation fluctuations—including a notable negative adjustment in 2025Q3—complicating the underlying earnings quality and making it difficult for investors to gauge the true recurring profitability of the firm's operations.

The erratic nature of EPS, which dropped from $6.02 in 2024Q4 to $4.85 in 2026Q1, suggests that non-operating items and accounting adjustments are playing a larger role in bottom-line performance than core operational improvements. This volatility may indicate that the company's earnings are more sensitive to accounting estimates than previously assumed.

CHE — Frequently Asked Questions

Quick answers to the most common questions about buying CHE stock.

What was Chemed Corporation's (CHE) revenue in 2025?

For fiscal year 2025, Chemed Corporation (CHE) reported total revenue of $2.53B. This represents a 740.0% increase compared to $301.2M in 1996.

Is Chemed Corporation (CHE) profitable?

Chemed Corporation (CHE) is profitable, generating $265.2M in net income for the fiscal year ending 2025 with a net profit margin of 10.5%.

What is Chemed Corporation's operating profit margin?

Chemed Corporation (CHE) reported an operating income of $338.2M, resulting in an operating profit margin of 13.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Chemed Corporation's gross profit and gross margin?

Chemed Corporation (CHE) generated $758.3M in gross profit for the year, representing a gross profit margin of 30.0%. This demonstrates the company's core pricing power and production efficiency.